Browsing by Subject "Delayed-Action Preparations"
Now showing items 1-9 of 9
-
A genetically engineered thermally responsive sustained release curcumin depot to treat neuroinflammation.
(J Control Release, 2013-10-10)Radiculopathy, a painful neuroinflammation that can accompany intervertebral disc herniation, is associated with locally increased levels of the pro-inflammatory cytokine tumor necrosis factor alpha (TNFα). Systemic ... -
Advances in opioid antagonist treatment for opioid addiction.
(The Psychiatric clinics of North America, 2012-06) -
Bupropion and Naltrexone in Methamphetamine Use Disorder.
(The New England journal of medicine, 2021-01)<h4>Background</h4>The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied.<h4>Methods</h4>We conducted this multisite, double-blind, two-stage, placebo-controlled trial with ... -
Controlled Release of Vancomycin and Tigecycline from an Orthopaedic Implant Coating Prevents Staphylococcus aureus Infection in an Open Fracture Animal Model.
(BioMed research international, 2019-01)Introduction:Treatment of open fractures routinely involves multiple surgeries and delayed definitive fracture fixation because of concern for infection. If implants were made less susceptible to infection, a one-stage procedure ... -
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
(Drug and alcohol dependence, 2014-05)The approval of extended release injectable naltrexone (XR-NTX; Vivitrol(®)) has introduced a new option for treating opioid addiction, but studies are needed to identify its place within the spectrum of available therapies. ... -
Extended-release ranolazine: critical evaluation of its use in stable angina.
(Vasc Health Risk Manag, 2011)Coronary heart disease is the major cause of morbidity and mortality throughout the world, and is responsible for approximately one of every six deaths in the US. Angina pectoris is a clinical syndrome characterized ... -
Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo.
(Journal of psychopharmacology (Oxford, England), 2012-06)This post-hoc analysis evaluated resilience as a predictor of treatment response in patients with posttraumatic stress disorder (PTSD). Data were pooled from two randomized, double-blind studies conducted with adult outpatients ... -
What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study.
(The Journal of clinical psychiatry, 2020-08-11)OBJECTIVE:An antidepressant medication switch often follows a failed initial trial with selective serotonin reuptake inhibitors (SSRIs). When, for whom, and how often second-step response and remission occur are unclear, ... -
Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone.
(The American journal on addictions, 2018-09)BACKGROUND AND OBJECTIVES:Long acting naltrexone has improved the therapy of opioid use disorder (OUD), and safe and effective withdrawal management during naltrexone induction may help advance treatment. Despite the uncertain ...
